Jon DeHaan Foundation Recognizes CARLENTM Cardiovascular Innovation
Nyra Medical has been selected for the prestigious Jon DeHaan Foundation Award, receiving a non-dilutive grant that recognizes both the innovation behind the CARLEN System and its potential to improve outcomes for patients with functional mitral regurgitation (FMR). Nyra is proud to join a distinguished group of global cardiovascular innovators working to shape the future of structural heart care.
Breakthrough Structural Heart Innovation
The Foundation is known for identifying and supporting breakthrough cardiovascular technologies with strong potential to improve patient outcomes and achieve commercial success. Award recipients are evaluated on factors including clinical need, technological differentiation, intellectual property, proof of concept, regulatory readiness, and commercialization potential.
For Nyra, the award serves as independent validation of both the CARLEN mitral valve repair System and the company’s broader clinical and business strategy. Importantly, the winning presentation showcased not only the technology itself, but also encouraging first-in-human clinical results demonstrating successful implantation and early clinical outcomes.
Emerging Leader in Mitral Valve Repair
Previous recipients have cited the award as a catalyst for fundraising, strategic partnerships, physician engagement, and clinical development. Nyra believes the recognition reinforces its position as one of the most promising emerging companies in structural heart innovation and highlights the potential of the CARLEN System to address patient populations underserved by current transcatheter mitral valve repair technologies.
mitral regurgitation
